Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study.

The use of anti-cholinergic drugs for counteracting neuroleptic induced extrapyramidal side-effects (EPS) is controversial. A possible increase in anticholinergic symptoms and a pharmacokinetic interaction are reported in literature. In order to determine these points, 22 schizophrenic patients were studied. Haloperidol (HL) was administered for 3 weeks and Orphenadrine (ORD) only in the second week of treatment. ORD reduced significantly EPS and its withdrawal led to a marked deterioration of EPS and psychopathological picture. There was an increase in HL plasma levels after starting ORD, and ORD plasma levels were positively related to EPS amelioration. Finally, prolactin seemed to be higher in those patients with EPS, particularly after ORD withdrawal.
AuthorsA C Altamura, M Buccio, G Colombo, A Terzi, C L Cazzullo
JournalL'Encéphale (Encephale) 1986 Jan-Feb Vol. 12 Issue 1 Pg. 31-6 ISSN: 0013-7006 [Print] FRANCE
PMID3698889 (Publication Type: Journal Article)
Chemical References
  • Receptors, Cholinergic
  • Orphenadrine
  • Haloperidol
  • Adult
  • Basal Ganglia Diseases (drug therapy)
  • Drug Evaluation
  • Drug Interactions
  • Drug Therapy, Combination
  • Female
  • Haloperidol (blood, metabolism, therapeutic use)
  • Humans
  • Kinetics
  • Male
  • Middle Aged
  • Orphenadrine (metabolism, therapeutic use)
  • Receptors, Cholinergic (metabolism)
  • Schizophrenia (drug therapy, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: